Sex Disparities in Chemo Use for Advanced Bladder Cancer

This article originally appeared here.
Share this content:
Sex Disparities in Chemo Use for Advanced Bladder Cancer
Sex Disparities in Chemo Use for Advanced Bladder Cancer

FRIDAY, June 10, 2016 (HealthDay News) -- Among patients with stage IV bladder cancer, women are less likely than men to receive systemic chemotherapy, and they have lower overall survival (OS), according to a study published online May 25 in Cancer.

Tracy L. Rose, M.D., M.P.H., from the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill, and colleagues compared sex differences in demographics, systemic chemotherapy administration, and OS for all patients diagnosed with stage IV bladder cancer from 1998 through 2010, identified using the National Cancer Data Base.

The researchers identified 23,981 patients (35 percent female). There was no difference in the Charlson-Deyo comorbidity score for men and women. Compared with men, women were less likely to receive systemic chemotherapy (45 versus 52 percent; adjusted relative risk, 0.91). Compared with men, women had a lower median OS (8.0 versus 9.8 months; P < 0.001). On multivariate analysis, women had lower OS, even after adjustment for administration of systemic chemotherapy (hazard ratio for death, 1.11).

"Women are less likely than men to receive systemic chemotherapy for advanced bladder cancer and this difference may partially account for the poorer OS observed in women," the authors write. "However, OS remains lower in women independent of chemotherapy use, and may be related to unmeasured comorbidities, functional status, or tumor biology."

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »